Epygen looking to raise Rs 300 Cr to propel Biosimilars in India - (The Economic Times via NewsPoints Desk)

  • Epygen Biotech plans to raise 300 crore Indian rupees in the next three years to fuel launch of its biosimilar pipeline, as reported The Economic Times.

  • The funding will help the company propel clinical trial programmes of its pipeline molecules in the field of oncology and cardiology, which are reportedly showing promise in protein expression and purification.

  • Epygen Biotech will launch a stepping stone biosimilar recombinant streptokinase for the cardiovascular segment in India by 2019.

  • Meanwhile, the company is upgrading its R&D capabilities by setting up a biopharmaceutical facility in Patalganga, Maharashtra, where Phase-I of the project is dedicated to E Coli based biosimilars for cardiovascular, oncology and rheumatology, while Phase-II of the project will produce mammalian cell based monoclonal antibodies for oncology.

  • FirstWord Reports: Providing insight, analysis and expert opinion on important Pharma trends and challenging issues <Click here>

To read more NewsPoints articles, click here.